The global secondary myelofibrosis therapeutics market, valued at USD 2.03 billion in 2024, is expected to witness steady growth through 2034. With a projected CAGR of 6.9%, the market is likely to reach USD 3.70 billion by 2034. This growth is driven by the rising prevalence of cancer and ongoing efforts to develop innovative therapies globally. As new treatments and clinical advance... https://www.expertmarketresearch.com/reports/secondary-myelofibrosis-therapeutics-market